Q1-FY26 · Dr. Ashutosh Raghuvanshi
We reported a consolidated topline figure of INR 2,167 crores, a growth of 16.6% over the quarter 1 of financial year 25.
FORTIS / language trends
Read confidence between the lines.
Fortis Healthcare · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q1-FY26 · Dr. Ashutosh Raghuvanshi
Our consolidated operating EBITDA increased 43.2% to INR 491 cr delivering a margin of 22.6% versus 18.4% in Q1 of financial year 25.
Q1-FY26 · Vivek Goyal
We are sticking to our guidance which we have provided in the beginning of the year 2% margin improvement.
Q1-FY27 · Dr. Ashutosh Raghuvanshi
The idea was that the doctors participate in the growth of the organizations and their interests and the company's interests are aligned. Clinicians help in many ways for the performance to improve in terms of controlling of the consumption for instance, other efficiency measures which are necessary to have a better profitability profile.
Q1-FY27 · Vivek Goyal
Oncology growth has become muted because of the CGHS/ECHS pricing and also our base has been increasing continuously. Since the growth was very high for about four to five years, the base has also become very large. We feel that oncology is going to be a big growth driver in terms of volumes but it is going to be in the range of 10-12% and not like 27% which used to be earlier.
Q1-FY27 · Dr. Ashutosh Raghuvanshi
We recognize that there has been a muted growth or rather a stagnant period for some time and that was a variety of factors including the brand change. Now those things are getting stabilized. We have about 10% growth seen in the last quarter and a lot of it has come from volume growth as well. This is definitely a sign of revival.